Pfizer invests in Ribon Therapeutics; Argenx gets PDUFA date extension
Massachusetts-based biotech Ribon Therapeutics has roped in a big name for some financial backing.
Ribon announced on Monday that Pfizer has invested $25 million into the biotech. Robert Rickert, Pfizer’s head of cancer immunology discovery, will be coming onto Ribon’s scientific advisory board. The startup will use the funds to support the development of its programs for oncology and immunology.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.